



# Identification of *cis/trans* isomers of menaquinone-7 in food as exemplified by dietary supplements



Arkadiusz Szterk\*, Adam Zmysłowski, Katarzyna Bus

National Medicines Institute, Department of Spectrometric Methods, 30/40 Chelmska, 00-725 Warsaw, Poland

## ARTICLE INFO

### Keywords:

Menaquinone-7  
Vitamin K<sub>2</sub>MK-7  
Impurities of dietary supplements  
*Cis/trans* isomers

## ABSTRACT

For the first time, the *cis/trans* isomer content of menaquinone-7 in food products has been identified and marked. A novel method of marking isomers of vitamin K<sub>2</sub>MK-7 in dietary supplements was developed and validated. Five different isomers of *cis/trans* vitamin K<sub>2</sub>MK-7 were identified. Identification of *cis/trans* isomers was performed by HRMS-QTOF, whereas their quantities were determined by using CAD and DAD detectors. In the majority of cases, the content of biologically active all *trans* vitamin K<sub>2</sub>MK-7 was below its declared content. The content of all *trans* K<sub>2</sub>MK-7 was in the range between 5.5 and 49 µg in pills. In one of the studied supplements, this vitamin was not found, regardless of the claim on the product label. The content of *cis/trans* isomers in certain dietary supplements exceeded the content of all *trans* K<sub>2</sub>MK-7 by up to 3.7 times.

## 1. Introduction

Vitamin K is a fat-soluble vitamin. The term vitamin K applies to a number of different chemical substances that contain a 2-methyl-1,4-naphthoquinone group and different lateral hydrocarbon chains at C<sub>3</sub> (Shea & Booth, 2007). The two naturally existing forms of vitamin K are vitamin K<sub>1</sub> (phylloquinone or phytomenadione), composed of a long phytyl lateral chain, and vitamin K<sub>2</sub> (menaquinones), a major feature of which is a long polyprenyl lateral chain (Fig. 1).

Vitamin K<sub>2</sub> consists of a group of chemical compounds, the composition of which can be expressed as K<sub>2</sub>MK-n, where n indicates the number of isoprenoid unsaturated units in a chain (usually, n is 4–13). One additional form of vitamin K is known as vitamin K<sub>3</sub> (menadiolone); however, this is a synthetic form and is a provitamin. Provitamin K<sub>3</sub> is not recommended for humans because it has certain toxic properties and may lead to haemolytic anaemia as well as allergic reactions (Hamidi & Cheung, 2014; Jinghe, Mizuta, & Ozaki, 2015).

The most important biological function of vitamin K in humans is its indispensable role in producing a haemostatic agent in the liver (first and foremost, prothrombin). However, there are different, new and important functions of vitamin K, such as its participation in forming osseous tissue, carboxylation of proteins, nucleic acid metabolism, and preventing certain types of haemophilia. Moreover, vitamin K has antibacterial and antimycotic properties and can be used to fight inflammation and pains (Geleijnse et al., 2004; Cockayne et al., 2006; Beulens et al., 2009, 2013; Vermeer, 2012). The most recent research indicates that vitamin K, mainly K<sub>2</sub>MK-7, participates in the

modification of proteins consisting of the gamma carboxylation of glutamic acid (GLU), the result of which is the formation of gamma carboxyglutamic acid (GLA), which has affinity to calcium ions. The best-known proteins of GLA include osteocalcin, MGP (MatrixGla Protein), and S-proteins. The largest affinity to calcium ions is that of a carboxylated form of osteocalcin, which has 3 residues of gamma carboxyglutamic acid (γ-carboxylated osteocalcin, Gla-OC). Osteocalcin binds calcium ions in the form of hydroxyapatite, constituting 70% of the total bone mass. A high level of non-carboxylated osteocalcin is connected with the risk of bone fractures.

An excessively low intake, mainly of vitamin K<sub>2</sub>MK-7, may reduce bone mineralization and result in an increase in the risk of fractures and occurrence of osteoporosis (Gundberg, Lian, & Booth, 2013; Plaza & Lamson, 2005; Yamaguchi, 2014). Moreover, it was demonstrated that menaquinones are a significantly more active form of vitamin K than vitamin K<sub>1</sub> with regard to biological activities other than participating in the blood coagulation process (Beulens et al., 2009; Spronk et al., 2003; Weber, 2001). Because vitamin K<sub>2</sub>MK-7 has a very important role in the bone-forming process and also reduces the risk of the occurrence of cardiovascular diseases (CVD), as well as calcification of blood vessels (Beulens et al., 2009; Gast et al., 2009; Geleijnse et al., 2004), it is important to provide humans with vitamin K<sub>2</sub>MK-7 as part of their diet.

It needs to be emphasized that the food sources of vitamin K for humans are mainly plants and algae. A high concentration of vitamin K<sub>1</sub> is found in green vegetables (e.g., broccoli, iceberg lettuce and spinach) and also in vegetable oils (e.g., soya oil, olive oil) (Booth, 2012). For

\* Corresponding author.

E-mail address: [szterkarkadiusz@gmail.com](mailto:szterkarkadiusz@gmail.com) (A. Szterk).




Fig. 1. Chemical structure of vitamin K.

humans, the most important form of vitamin K<sub>2</sub> is vitamin K<sub>2</sub>MK-7, which is present at low concentrations in animal products, such as eggs and meat, as well as at high concentrations (1200 µg 100 g<sup>-1</sup>) in fermented products, such as natto, cheese, curd and sauerkraut (Hamidi & Cheung, 2014; Scheiber et al., 2015; Weber, 2001). However, this vitamin is found in few food products in comparison with vitamin K<sub>1</sub>, such that its daily and long-term supply is limited. There is another problem with human's demand for this vitamin. At the moment, there are no standards for the human daily demand for vitamin K<sub>2</sub>MK-7. However, by analysing the global literature concerning the influence of menaquinones on humans and the dietary intake of vitamin K<sub>1</sub> and K<sub>2</sub>, it can be concluded that a daily intake of vitamin K<sub>2</sub> for an adult woman should not be greater than 90 µg d<sup>-1</sup> and for men greater than 120 µg d<sup>-1</sup>, which means that the daily demand for vitamin K should not be exceeded (Beulens et al., 2013). On the basis of the current state of knowledge, it is thought that menaquinones in a human diet should constitute approximately 25% of all forms of vitamin K (K<sub>1</sub> and K<sub>2</sub>) (Nimptsch, Rohrmann, & Linseisen, 2008; Schurgers & Vermeer, 2000). On the basis of the recommendations of the European Food Safety Authority (Bresson et al., 2008), the daily intake of menaquinones for adult women should be approximately 30 µg d<sup>-1</sup> and for adult males approximately 50 µg d<sup>-1</sup>. Providing the intake of such quantities of vitamin K<sub>2</sub> in a diet is not easy, because this vitamin is not as common in food as vitamin K<sub>1</sub>. It seems that the best method of complementing the human diet with vitamin K<sub>2</sub> may be dietary supplements that are commonly available on the global market. There is a major problem with dietary supplements in Europe and all over the world in terms of their quality. Essentially, the sole requirement of food law, in European and other countries, is that a product is safe for human consumption. Less attention is paid to the chemical quality of dietary supplements. The chemical quality of dietary supplements is very important from the point of view of vitamin K<sub>2</sub>MK-7. This vitamin is obtained either from natural sources, mainly natto (Sato et al., 2001), or in a significantly more economical way, by chemical synthesis (Baj et al., 2016; Daines, Payne, Humphries, & Abell, 2003; Sato, Inoue, & Saito, 1973; Snyder & Rapoport, 1974). K<sub>2</sub>MK-7 preparations obtained from natto contain 100% of the *trans* form of K<sub>2</sub>MK-n, whereas K<sub>2</sub>MK-7 constitutes more than 95% of all menaquinones (Kamao et al., 2007; Sato et al., 2001; Schurgers & Vermeer, 2000; Walther, Karl, Booth, & Boyaval, 2013). There are no reports in the literature ascertaining the presence of the *cis* form in natural preparations of K<sub>2</sub>MK-7. The *cis/trans* isomers of menaquinones are ascertained during chemical synthesis (Baj et al., 2016; Daines et al., 2003; Sato et al., 1973; Snyder & Rapoport, 1974). Only *trans* menaquinones demonstrate biological activity (Beulens et al., 2013; Shearer & Newman, 2008; Yamaguchi, 2014). The studies conducted by Lowenthal and Rivera (1979) demonstrated that the *cis* forms of vitamin K have 1% of the biological activity of the *trans* form. The results of this research were

confirmed by other researchers (Huang et al., 2012; Knauer, Siegfried, Willingham, & Matschiner, 1975; SCCS., 2010). Moreover, in accordance with the opinion of the FAO issued in 2008, it is only the *trans* form of menaquinones, mainly including K<sub>2</sub>MK-7, that is important for humans from the point of view of its biological functions, and it can be found in different preparations, including dietary supplements, facilitating compensation of the deficits of this vitamin in the diet. In the global literature, there are no scientific reports concerning the content of the *cis/trans* form of menaquinones in dietary supplements. Moreover, there are virtually no studies of supplements in terms of the content of this vitamin, which is currently very fashionable and frequently found in supplements.

The objective of this dissertation was to study a few of the most popular dietary supplements containing vitamin K<sub>2</sub>MK-7 in terms of the presence of the *trans* form as well as the *cis/trans* form. In this study, a new analytical method that is selective for *cis/trans* isomers of vitamin K<sub>2</sub>MK-7 was developed. An additional objective of this dissertation was to verify whether the declaration concerning the content of vitamin K<sub>2</sub>MK-7 that is placed on it is compatible with the actual composition of the supplement.

## 2. Materials and methods

### 2.1. Research materials

The research material consisted of 8 different dietary supplements of vitamin K<sub>2</sub>MK-7 in the form of hard pills purchased from 10 different chemists. Three of the supplements were produced in Poland (Polish producer 1: Natural Supplements “naturalna witamina K<sub>2</sub> + D<sub>3</sub> forte”; Polish producer 2: “Molekin D<sub>3</sub> + K<sub>2</sub>”; Polish producer 3: Polski Lek “witamina D<sub>3</sub> + K<sub>2</sub>”), three in Norway (Norway producer 1: “Menna Q7 witamina 30 caps.” Norway producer 2: “Menna Q7 witamina 30 caps. forte” Norway producer 3: “Menna Q7 witamina 60 caps.”), one in Sweden (“Kinon”), and one in the USA (“natural vitamin K<sub>2</sub> from natto”). All supplements were preparations with labels that declared the content of vitamin K<sub>2</sub>MK-7 or a mixture of vitamin K<sub>2</sub>MK-7 and vitamin D<sub>3</sub>.

### 2.2. Chemicals

Tetrahydrofuran (THF) for analysis EMPARTA® ACS, methanol anhydrous, 99.8%, methanol hypergrade for LC-MS LiChrosolv®, 2-propanol hypergrade for LC-MS LiChrosolv®, *n*-hexane hypergrade for LC-MS LiChrosolv®, ammonium acetate for LC-MS LiChropur®, acetic acid 100% for LC-MS LiChropur®, menaquinone-7 (vitamin K<sub>2</sub>MK-7) United States Pharmacopeia (USP) Reference Standard, vitamin K<sub>2</sub>MK-7 100 µg ml<sup>-1</sup> in acetonitrile, and certified reference material (check standard) were purchased from SIGMA Aldrich, Poland, Gliwice.

### 2.3. Sample preparation

After determining the average mass of a pill (by means of weighing 30 different pills), the pills were crushed in a mortar. Appropriate mass of crushed pills, which corresponds to the determined average mass of pills was placed into a 30 ml glass centrifuge test tube, and 20 ml of THF was added. The test tube was plugged with a Teflon cork and placed into an ultrasonic cleaning device, in which the vitamin was extracted for 30 min (22 kHz and 30 W). Afterwards, the sample was centrifuged (speed: 4000 rpm) for 10 min at 4 °C. The supernatant was poured into a round-bottom laboratory flask and evaporated until dry in a vacuum evaporation device at 25 °C, while protecting the sample against light (the laboratory flask was wrapped in aluminium foil). The dry remnant was dissolved in 1 ml of the mixture of methanol: THF at a proportion 7:3 v/v. Five microliters of the sample was placed into a chromatography column.

#### 2.4. Chromatographic analysis and detection: DAD, CAD and QTOF

A UHPLC Ultimate 3000 (Dionex Thermo Fisher Scientific, Sunnyvale, California, USA) system consisting of a pump, degasser, autosampler, column heater detector (analytical  $\lambda = 268$  nm) and pulse damper coupled with an ESA Corona CAD (Charged Aerosol Detectors) instrument was used. The CAD response range was 100 pA, with no filter selected. Nitrogen from a nitrogen generator regulated at 0.24 MPa was introduced to the detector. Data processing was carried out with Chromeleon 6.8 and Chromeleon Validation ICH software (Dionex) and the chromatographic conditions were optimized with DryLab 2000 Plus software (Molnar Institute). To determine the peak elution order, a mass spectrometer maXis 4G from Bruker Daltonic (Billerica, Massachusetts, USA) was used. The chromatographic conditions for MS analysis were the same as for UHPLC–DAD–CAD. The QTOF settings were electrospray ionization (ESI) in positive ion mode, dry gas (nitrogen) flow rate of  $8.0 \text{ l min}^{-1}$ , dry heater at  $180^\circ\text{C}$ , capillary voltage of 4500 V and end plate offset of -500 V. MS data were recorded in full scan mode (from 50 to 3000  $m/z$ ). The mass spectrometer was used in high resolution mode ( $R = 60,000$ ), and an internal calibrant (1 mM aqueous solution of sodium formate) was used to make a precise mass measurement. Chromatographic separation was conducted with the use of a COSMOSIL cholest column (2.0 mm AND.D.  $\times$  150 mm) with a pore diameter of 3.0  $\mu\text{m}$ . The work was conducted in a gradient system (phase A: 6.5 mM ammonium acetate and 6.5 mM acetic acid in the 10% solution of water in methanol). Phase B also contained 6.5 mM ammonium acetate and 6.5 mM acetic acid in the following solution: 2-propanol:*n*-hexane in the proportion: 2:1 (v/v). For preparing phase B, ammonium acetate and acetic acid were dissolved for 10 min in an ultrasound cleaning device before combining with *n*-hexane. The following gradient system was applied: 0–5 min 18% B, 5–30 min 40% B, 30–32 min 40% B, 32–33 min 18% B, 30–35 min 18% B (balancing columns until the initial conditions are restored). Chromatographic separation was conducted with a constant flow of mobile phase ( $350 \mu\text{l min}^{-1}$ ) at a temperature of  $40^\circ\text{C} \pm 0.1^\circ\text{C}$ .

#### 2.5. Marking vitamin K<sub>2</sub>MK-7 in dried natto

Marking vitamin K<sub>2</sub>Mk-7 in natto was conducted in accordance with Schurgers and Vermeer (2000).

#### 2.6. Method validation

Quantitative analysis was performed by a standard-addition method. In this way, besides estimating the unknown amount of the analytes occurring in the different dietary supplements, it was possible to evaluate the sensitivity (LOD and LOQ) and linear dynamic range in the various matrices. The recoveries, matrix effect, linearity, accuracy (repeatability and reproducibility), limits of detection (LOD) and limits of quantitation (LOQ) were calculated after determining the levels of all *trans* vitamin K<sub>2</sub>MK-7 in the specific food.

##### 2.6.1. Preparation of stock, spiking solutions, LOD and LOQ calculation

A primary stock solution of all *trans* vitamin K<sub>2</sub>MK-7 ( $5.0 \text{ mg ml}^{-1}$ ) was prepared in a methanol: THF (7:3 v/v) solution. Spiking solutions of the analyte (10, 20 and  $\mu\text{g ml}^{-1}$ ) were prepared with the mixed intermediate solution of the analyte, and all of these solutions were stored at  $-20^\circ\text{C}$ , while protecting it against light. Twelve calibration curve points (0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8, 25.6, 51.2, 102.4, 204.8 and  $250.0 \mu\text{g ml}^{-1}$ ) were prepared by spiking the matrix after evaporation and sample extraction. The LOD and LOQ were calculated. The LOD was defined as  $3 \times$  standard deviation of the blank, and the LOQ was defined as  $10 \times$  the standard deviation of the blank. The mean LOD and LOQ from each sample was calculated, with  $n = 10$  independent of detector used.

##### 2.6.2. Recovery

The recovery of the analyte (all *trans* vitamin K<sub>2</sub>MK-7) was studied with the application of the standard addition method. The recovery was studied at three different levels of enrichment (10  $\mu\text{g}$ , 20  $\mu\text{g}$  and 30  $\mu\text{g}$  per ml of a final solution, which is equal to the average mass of a pill). The recovery was studied independently for each supplement and detector used (DAD, CAD and QTOF). Global recovery was calculated for each level of fortification (the average of all the studied dietary supplements,  $n = 10$ ), and also for each detector.

##### 2.6.3. Matrix effect (MF)

MF was calculated by  $100\% - \{[\text{peak area of K}_2\text{MK-7 in the presence of the matrix (post extracted sample)}/\text{mean peak area of K}_2\text{MK-7 in the absence of the matrix (all trans K}_2\text{MK-7 in methanol: THF solution)}] \times 100\%\}$ . The mean MF was calculated from  $n = 10$  independent of detector used.

##### 2.6.4. Precision and accuracy

Precision and accuracy were evaluated by intra-day and inter-day parameters. Intra-day precision was calculated as % CV from the mean amount of quality control sample (all-*trans* K<sub>2</sub>MK-7 United States Pharmacopeia (USP) Reference Standard,  $n = 10$  and concentration  $20 \mu\text{g ml}^{-1}$ ) by a single person using the same equipment, under the same conditions, and in a short period of time (one day). Inter-day precision was calculated as % CV from the mean amount of the quality control sample (all *trans* K<sub>2</sub>MK-7 United States Pharmacopeia (USP) Reference Standard,  $n = 10$  and concentration  $20 \mu\text{g ml}^{-1}$ ) by three independent people using the same equipment, under the same conditions, and over a long period of time (3 days). The accuracy of this analytic method was assessed as the percentage relative error ( $100 \times [\text{found} - \text{added}]/\text{added}$ ). The analytical standard was added after the whole procedure of sample preparation and  $20 \mu\text{g}$  of all *trans* K<sub>2</sub>MK-7 per sample was always added (the final concentration was  $20 \mu\text{g ml}^{-1}$ ). The accuracy was measured for one randomly selected dietary supplement,  $n = 10$ . Precision and accuracy were determined according to Yilmaz, Kadioglu, Meral, and Onganer (2012).

### 3. Results

To mark possible *cis/trans* isomers of menaquinone-7 in the dietary supplements, a stereo-selective chromatography column filled with chemically modified silica containing approximately 20% basic cholesterol was used. Geometric isomers of vitamin K<sub>2</sub>MK-7 were marked with the application of a DAD and charged aerosol detectors (CAD). Identification of the *cis/trans* isomers of vitamin K<sub>2</sub>MK-7 was conducted by using a high-resolution quadrupole analyser coupled with a time of flight analyser (QTOF).

Fig. 2 presents examples of the chromatograms of the analysed dietary supplements, an analytical standard of all *trans* vitamin K<sub>2</sub>MK-7, and the extract obtained from dried natto, in accordance with Schurgers and Vermeer (2000). In certain samples (in particular, of the Swiss producer and Polish producer-1), apart from all *trans* vitamin K<sub>2</sub>MK-7, the presence of different chemical compounds was ascertained as well (they are identified with a question mark). An attempt was made to identify unknown substances by using a high-resolution mass spectrometer combined with a high-efficiency liquid chromatograph (HRMS–QTOF). Fig. 1 in the Supplementary materials shows the fragmentary spectra of the supplementary materials of chromatographically separated substances. The chemical compound known as C4 (Fig. 1 Supplementary materials) is all *trans* vitamin K<sub>2</sub>MK-7, with an  $m/z = 667.00$ , which is a pseudo-molecular ion formed as the result of the adduction of  $\text{NH}_4^+$  to  $649.00 (\text{M} + \text{H} + \text{NH}_3)^+$ .

The retention time of the chemical compound known as C4 and its fragmentary spectrum are identical to those of the analytical standard of vitamin K<sub>2</sub>MK-7 (Figs. 2 and 3). The remaining recorded spectra of unknown substances C1, C2, C3, C5, and C6 (Fig. 1 Supplementary

Fig. 2. Example chromatograms from CAD detection of an analytical standard vitamin of all *trans* K<sub>2</sub>MK-7, various dietary supplements from various producers from various canaries and chromatograms of dry natto extract. ? – unknown substance.





Fig. 3. Spectrum of all *trans* vitamin K<sub>2</sub>MK-7.

materials) do not statistically differ from the spectrum of all *trans* vitamin K<sub>2</sub>MK-7. Moreover, these substances undergo ionization in precisely the same way as all *trans* vitamin K<sub>2</sub>MK-7 ( $M + H + NH_3$ )<sup>+</sup>, which results in the formation of an adduct of  $m/z = 667.00$  and a pseudo-molecular ion of a chemical compound with a theoretical mass of  $649.00 \text{ g mol}^{-1}$ . As a result of the fragmentation of ion  $m/z = 667.00$ , there is decrease in the amount of ammonium radical, which causes the formation (in each case) of a fragment of  $m/z = 649.5$  and is a pseudo-molecular ion with the molecular formula  $C_{46}H_{64}O_2$ . For all the studied substances visible in Fig. 2 and Fig. 1 (Supplementary materials), the mass measurement error is smaller than 1.5 ppm and the isotope

profiles (mSigma) have low values from adjusting the molecular formula amount to 99.9999%. Larger values of mSigma (an isotope profile not so well adjusted) are observed in the case of chemical compounds C1 and C6, which result from the relatively low concentrations of these substances, causing the heaviest isotopes to appear at the limit of detection of the mass spectrometer.

From this research, it is possible to determine that the identified unknown substances (C1, C2, C3, C5, and C6 Fig. 1 Supplementary materials) are likely to be the *cis/trans* isomers of vitamin K<sub>2</sub>MK-7, which, for the first time, were identified in food. Unfortunately, in the case of the use of HRMS, it is not possible to determine where in the isoprene chain of menaquinone-7 the *cis* configuration exists.

Table 1 presents the validation parameters of the developed method of marking vitamin K<sub>2</sub>MK-7 in dietary supplements. The developed method was applied to marking vitamin K<sub>2</sub>MK-7 in dietary supplements available on the market in the form of a hard pill. Table 2 includes the results for the content of the *cis/trans* isomers of vitamin K<sub>2</sub>MK-7 in the studied samples.

In Table 1, LOD, LOQ, and linear values are expressed in  $\mu\text{g ml}^{-1}$ ; however, a more practical unit should be  $\mu\text{g}$  in the pill. However, because the masses of pills are very different (Table 2), it was decided to express all units in  $\mu\text{g ml}^{-1}$  because in accordance with the described procedure of preparing a sample, one pill of the studied supplement is prepared in 1 ml of the final solution (the mixture of methanol:THF, 7:3 v/v). On the basis of the results in Table 1, a major feature of the developed method is a sufficient sensitivity in relation to marking vitamin K<sub>2</sub>MK-7 in dietary supplements. The sensitivity of the method (LOD and LOQ) depends on the detector. The highest sensitivity (the lowest LOD

**Table 1**  
Validation parameters of all *trans* K<sub>2</sub>MK-7 in dietary supplements.

	DAD detector	CAD detector	QTOF detector (SIM, $m/z = 666,5 \pm 0,5 m/z$ )
LOD [ng ml <sup>-1</sup> ]	378.7	678.2	206.5
% CV	8.2	5.5	10.4
LOQ [ng ml <sup>-1</sup> ]	1262.4	2260.8	690.0
% CV	0.6	0.1	8.1
<i>Recovery</i>			
Spiked level 1: 10 µg ml <sup>-1</sup> [%]	89.1	90.1	91.3
SD	1.2	0.2	4.6
Spiked level 2: 20 µg ml <sup>-1</sup> [%]	90.2	90.0	92.6
SD	1.6	0.6	5.9
Spiked level 3: 30 µg ml <sup>-1</sup> [%]	96.5	95.8	93.7
SD	0.6	0.5	3.5
Matrix effect (ME) [%]	< 5	< 5	< 5
SD	–	–	2.2
Linear (range in µg ml <sup>-1</sup> and R <sup>2</sup> )	1.3–250 µg ml <sup>-1</sup> R <sup>2</sup> = 0.998	2.3–250 µg ml <sup>-1</sup> R <sup>2</sup> = 0.999	Very low, for example: 2–4 µg ml <sup>-1</sup> R <sup>2</sup> = 0.991, but for 2–20 µg ml <sup>-1</sup> R <sup>2</sup> = 0.870
<i>Precision and accuracy</i>			
Intra-day precision in % CV	0.5	0.6	7.7
Intra-day accuracy	2.5	2.8	5.2
Inter-day precision in % CV	3.3	3.9	9.1
Inter-day accuracy	–1.9	–2.1	–4.3

and LOQ) was obtained by using the mass spectrometer (QTOF). However, in the case of QTOF, the linear character of the method is very low, which virtually disqualifies this detector in terms of quantitative marking. A QTOF is the perfect tool for the identification or confirmation of marked substances.

For marking vitamin K<sub>2</sub>MK-7 in dietary supplements, a DAD or CAD are perfect. The LOD and LOQ for these detectors are sufficient to mark the *cis/trans* form of vitamin K<sub>2</sub>MK-7. Moreover, a major feature of these detectors is the very wide range of linearity from LOQ to 250 µg ml<sup>-1</sup> (virtually µg pill<sup>-1</sup>). The retrieval in the method statistically does not depend on the detector, which results from a small influence of the matrix (ME < 5%) and is within the range 89–96.5%. A major feature of the developed method is its being precise, which, in the case of DADs and CADs, amounts to an intra-day precision of 0.5–0.6% and an accuracy of 2.5–5.2%, whereas the inter-day precision amounts to 3.3–3.9% and the accuracy from –1.9 to –4.3% (Table 1). All the studied validation parameters were determined on the basis of the isomer of all *trans* K<sub>2</sub>MK-7. Unfortunately, there are no forms of *cis/trans* vitamin K<sub>2</sub>MK-7 available for sale. However, the application of a charged aerosol detector (CAD) for quantitative marking essentially eliminates the problem of the lack of standards for *cis/trans* isomers because the signal of this detector does not depend on the chemical structure of the molecules but only on their concentration. For that reason, the developed method of marking all *trans* K<sub>2</sub>MK-7 with a CAD was used for marking the different form of vitamin K<sub>2</sub>MK-7 in the dietary supplements of this vitamin available on the pharmaceutical market.

Based on this research (Table 2) it can be concluded that the composition of dietary supplements in terms of the content of vitamin

K<sub>2</sub>MK-7 is very varied. In the dietary supplement produced in USA, despite label claim, vitamin K<sub>2</sub>MK-7 was not detected. The remaining supplements contained, without exception, *trans* K<sub>2</sub>MK-7 in the quantity between 5.5 µg pill<sup>-1</sup> and 248.1 µg pill<sup>-1</sup>. All the studied supplements, with the exception of the Polish product (of the third producer), contained a varied content of *cis/trans* isomers K<sub>2</sub>MK-7; however, the smallest share of them was ascertained in the case of the supplements produced in Poland and Norway. In the set of the studied samples, it is only the dietary supplement of vitamin K<sub>2</sub>MK-7 from the Norwegian producer that contained the declared content of all the *trans* vitamin K<sub>2</sub>MK-7. In the remaining supplements, the vitamin was either not ascertained, or its content was several times lower.

#### 4. Discussion

Marking *cis/trans* isomers of vitamin K<sub>2</sub>MK-7 was possible by means of the application of a stereo-selective chromatography column that was composed of chemically modified silica containing approximately 20% cholesteryl. This type of column was used by Nannapaneni, Jalalpure, Muppavarapu, and Sirigiri (2017) to separate *cis* and *trans* isomers of vitamin K<sub>1</sub> in biological samples. On the basis of the obtained mass spectra (Fig. 1 Supplementary materials), the separated substances, shown in Fig. 2, are *cis/trans* isomers of vitamin K<sub>2</sub>MK-7. When ionized, all these chemical compounds produce a pseudo-molecular ion with a theoretical  $m/z = 667.00$  and are adducts of NH<sub>4</sub><sup>+</sup> with a theoretical mass of 649.00. The mechanism of ionization can be expressed in the form (M+H+NH<sub>3</sub>)<sup>+</sup>. The formation of the NH<sub>4</sub><sup>+</sup> adduct was connected with the fact that in the mobile phases used for chromatographic separation, ammonium acetate was applied as a phase

**Table 2**  
All *trans* K<sub>2</sub>MK-7 and *cis/trans* isomers contents in dietary supplements obtained from local markets, n = 10.

Sample	Average weight of pill [mg]	SD	Declared amount of K <sub>2</sub> MK-7 vitamin by producer [µg pill <sup>-1</sup> ]	All <i>trans</i> K <sub>2</sub> MK-7 [µg pill <sup>-1</sup> ]	SD	Sum of <i>cis/trans</i> isomers of vitamin K <sub>2</sub> MK-7 [µg pill <sup>-1</sup> ]	SD
Polish producer 1	350.2	11.0	100 (from natto)	22.6	0.9	81.5	1.1
Polish producer 2	322.9	2.7	75 (no data)	49.1	3.7	3.2	0.5
Polish producer 3	252.5	2.2	75 (no data)	5.5	0.1	< LOQ	–
Norway producer 1	564.5	19.1	100 (from natto)	139.8	1.9	15.7	0.3
Norway producer 2	677.5	42.9	200 (from natto)	248.1	3.4	30.5	0.2
Norway producer 3	623.3	31.5	100 (from natto)	133.2	1.1	16.4	0.2
Switzerland producer	389.1	3.9	100 (from natto)	11.9	1.1	31.2	1.0
US producer	620.4	30.9	100 (from natto)	< LOD	–	< LOD	–

modifier. The formation of such an adduct is typical for these phases (Fouquet, Humbel, & Charles, 2011; Huang & Siegel, 1999). Adducts of  $\text{NH}_4^+$  are specific as fragments of these ions ( $\text{M} + \text{H}$ )<sup>+</sup> form, as well as neutral  $\text{NH}_3$ . Ions ( $\text{M} + \text{H}$ )<sup>+</sup> undergo fragmentation, leading to a typical spectrum of menaquinones-7 (Fig. 3 and Fig. 1 Supplementary materials). The use of HRMS (QTOF) makes it impossible to ascertain where the *cis* bond is located in the isoprenoid chain. Both *cis* and *trans* isomers undergo fragmentation in an identical way (Carlone & Anet, 1983; Huang et al., 2012). According to quality, dietary supplementation and biological functions, identification of the isomer of all *trans* K<sub>2</sub>MK-7 and *cis/trans* isomers of K<sub>2</sub>MK-7 is sufficient. To determine where the *cis* bonds are found in an isoprenoid chain of vitamin K<sub>2</sub>MK-7, it is necessary to conduct fractionation of the identified substances that are shown in Fig. 2 and determine their chemical structure by NMR.

Studying the *cis/trans* isomers of vitamin K<sub>2</sub>MK-7 is very important from a biological point of view. Only the *trans* forms of vitamin K<sub>1</sub> and K<sub>2</sub> have biological activity. The *cis* or *cis/trans* forms (in the case of menaquinones) do not have biological activity, or it is at a very low level (Beulens et al., 2013; Huang et al., 2012; Pucaj, Rasmussen, Møller, & Preston, 2011; Yamaguchi, 2014). This was shown for vitamin *cis* K<sub>1</sub> (Lowenthal & Rivera, 1979) and mixtures of *cis/trans* isomers K<sub>2</sub>MK-6 (Weber & Wiss, 1959). There are no biological data concerning the activity, including the toxicity, of the *cis/trans* form of vitamin K<sub>2</sub>MK-7. However, on the basis of the biological function of the all *trans* isoprene units, it is possible to ascertain that *cis* isomers or *cis/trans* isomers constitute chemical pollution, which has no positive biological role, as does all *trans* vitamin K<sub>2</sub>MK-7. Geometric isomerization of isoprenoid units in vitamin K<sub>2</sub>MK-7 is possible in a few cases. *Cis* isomers are formed during the course of the chemical synthesis of this vitamin (Baj et al., 2016; Daines et al., 2003; Sato et al., 1973; Snyder & Rapoport, 1974) and also during the course of incorrect technological processes, the objective of which is to obtain different preparations of vitamin K<sub>2</sub>MK-7, mainly by the impact of light (in particular, UV radiation), which causes geometrical isomerization of the isoprenoid units in menaquinone-7 (Huang et al., 2012). Afterwards, oxidization catalysed by a high temperature, or the impact of radicals, causes the formation of epoxides and *cis* isomers at different locations in the isoprenoid chain of vitamin K<sub>2</sub>MK-7 (Yamada, Aoki, & Tahara, 1982). Such a process may take place while generating microcapsule preparations of vitamin K<sub>2</sub>MK-7, which is a stock raw material for hard pills and capsules. It can be presumed that the geometrical isomerization of all *trans* vitamin K<sub>2</sub>MK-7 occurs as the result of the autoxidation processes in the course of storing dietary supplements, which are in contact with oxygen in the atmosphere, light and elevated temperature. Unfortunately, there are no relevant data in the literature. However, we found different *cis/trans* isomers of vitamin K<sub>2</sub>MK-7. Moreover, in certain supplements, the sum of the *cis/trans* isomers was significantly larger than the content of the pure form of *trans* K<sub>2</sub>MK-7 (Fig. 2, Table 2). The explanation for the occurrence of a large quantity of *cis/trans* isomers of K<sub>2</sub>MK-7, in particular in supplements from the first Polish producer and Swiss producer, is that they are likely the result of using synthetic vitamin K<sub>2</sub>MK-7. The producers of these supplements declare that the vitamins contained in them were from natural sources (extract from natto). However, natto does not contain the *cis/trans* form of vitamin K<sub>2</sub>MK-7, it only contains *trans* K<sub>2</sub>MK-7, as shown by the chromatogram of the extract of natto obtained from dried natto in Fig. 2 (J), which matches the data in the literature (Kamao et al., 2007; Sato et al., 2001; Schurgers & Vermeer, 2000; Walther et al., 2013). In turn, during chemical synthesis of vitamin K<sub>2</sub>MK-7 *cis/trans* isomers in relation to the pure form, all *trans* isomers are formed at a ratio of 1:3 or 1:2 in/in or not at all, depending on the method of synthesis (Baj et al., 2016; Daines et al., 2003; Sato et al., 1973; Snyder & Rapoport, 1974). In the analysed samples, large quantities of *cis/trans* isomers were found, indicating the use of synthetic vitamin K<sub>2</sub>MK-7 as well as a likely adverse impact of the technological process generating vitamin K<sub>2</sub>MK-7 in pills. These factors might have

contributed to the occurrence of the large quantity of *cis/trans* isomers of vitamin K<sub>2</sub>MK-7 in the studied samples. In the remaining supplements, no more than 5% *cis/trans* isomers were found. Moreover, only one geometric isomer of this vitamin was found (Fig. 2). The vitamins in these supplements were obtained either from natto or were synthesized by using a method similar to the process described by Baj et al. (2016). The presence of a small quantity of isomeric *cis/trans* was most likely the result of the technological process used to prepare vitamin K<sub>2</sub>MK-7, which is the basis for obtaining a hard pill. Most likely, it was from a microcapsule preparation, during which the geometrical isomerization of all *trans* K<sub>2</sub>MK-7 occurred.

Apart from the occurrence of *cis/trans* isomers of menaquinone-7, a serious problem with the declared content of vitamin K<sub>2</sub>MK-7 was found. Only in supplements produced in Norway was the declared content of vitamin K<sub>2</sub>MK-7 the same as the actual value. Moreover, a larger content of all *trans* vitamin K<sub>2</sub>MK-7 was found in the Norwegian supplements, which was likely caused by the distant expiration date of these supplements. During production, the producers of supplements assume a certain surplus of vitamin so that by the expiration date its content is the same as the declared value. In all the remaining studied supplements, the content of vitamin K<sub>2</sub>MK-7 was below the declared value, and in the case of the American supplement, it was not found at all. The results of this study allow us to formulate a number of conclusions. Producers of dietary supplements take advantage of the lack of legal regulations regarding official control of the quality of dietary supplements. In accordance with European law and with laws in different countries, dietary supplements are treated as food, which means they only have to be safe. There are no effective regulations or solutions that would force producers to thoroughly control the quality of supplements as is the case for producing medicinal products, which leads the actual content of vitamin in the final product to be different from that declared by the producer. This difference may result from the dishonesty of producers or errors in the supplement production process (errors in recipes) as well as from oxidation or disintegration of the vitamin during production, transport or storage of supplements. The high content of *cis/trans* isomers of vitamin K<sub>2</sub>MK-7 in reference to all *trans* K<sub>2</sub>MK-7 results in the need for determining the biological activity as well as the toxicity of the *cis/trans* forms of K<sub>2</sub>MK-7. Moreover, results for supplements of vitamin K<sub>2</sub>MK-7 in the form of hard pills were presented. This vitamin is, however, the most frequently sold in the form of heterogeneous capsules, in which it is dissolved in different oils. It is known that vitamin K<sub>2</sub>MK-7 is susceptible to oxidation; therefore, there is a question regarding the quality of vitamin K<sub>2</sub>MK-7 supplements.

## 5. Conclusion

A novel method that produces all *trans* vitamin K<sub>2</sub>MK-7 and *cis/trans* isomers in dietary supplements sold in the form of hard pills was developed. The method is based on chromatography with detection (DAD, CAD, and also QTOF) and made it possible to separate and mark 5 different *cis/trans* isomers of vitamin K<sub>2</sub>MK-7, as well as the isomer of all *trans* K<sub>2</sub>MK-7. The developed and validated method was used to study the content of different isomeric forms of vitamin K<sub>2</sub>MK-7 in different commercially available dietary supplements produced in different countries. This study demonstrated that there were large variations of the content of vitamin K<sub>2</sub>MK-7 in the studied dietary supplements; usually, its concentration was below the declared content. In one of the supplements, it was not found at all. Moreover, large quantities of the *cis/trans* isomers of vitamin K<sub>2</sub>MK-7 were identified, which likely did not have vitamin K<sub>2</sub> activity. Alternatively, vitamin K<sub>2</sub> activity might have been significantly reduced. Different contents of vitamin K<sub>2</sub>MK-7 in the studied dietary supplements and the occurrence of large quantities of *cis/trans* isomers may indicate dishonesty of producers who claim that they use natural extracts of natto, which do not contain *cis* isomers of this vitamin. It can be presumed, that, in reality,

producers use cheap preparations of vitamin K<sub>2</sub> obtained by means of chemical synthesis and use production methods in which *cis/trans* isomers or the sold product are chemically transformed (e.g., oxidized) during storage, causing the transformation of all *trans* vitamin K<sub>2</sub>MK-7 into *cis/trans* isomers. For the first time, dietary supplements with vitamin K<sub>2</sub>MK-7 were studied. It was determined that there is a serious problem with their quality, which is caused by a number of factors.

### Acknowledgements

This research is purely scientific. The aim of the research was not to compare products between themselves (for example - in relating range of the safety and of the quality), but merely to determine the actual state of the chemical form of vitamin K<sub>2</sub>MK-7 in dietary supplements and the names of the products mentioned are only intended to enable the reproduction of the method and the results to other researchers. Moreover this work was co-financially supported by Polish Ministry of Science and Higher Education statutory grant number: 1.34/2017.

### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.foodchem.2017.10.001>.

### References

- Baj, A., Walejko, P., Kutner, A., Kaczmarek, Ł., Morzycki, J. W., & Witkowski, S. (2016). Convergent synthesis of menaquinone-7 (MK-7). *Organic Process Research and Development*, 20(6), 1026–1033.
- Beulens, J. W., Bots, M. L., Atsma, F., Bartelink, M. L., Prokop, M., Geleijnse, J. M., ... van der Schouw, Y. T. (2009). High dietary menaquinone intake is associated with reduced coronary calcification. *Atherosclerosis*, 203, 489–493.
- Beulens, J. W. J., Booth, S. L., van den Heuvel, E. G. H. M., Stoecklin, E., Baka, A., & Vermeer, C. (2013). The role of menaquinones (vitamin K2) in human health. *British Journal of Nutrition*, 110, 1357–1368.
- Booth, S. L. (2012). Vitamin K: Food composition and dietary intakes. *Food and Nutrition Research*, 56(5505), 1–5.
- Bresson, J. L., Flynn, A., Heinonen, M., Hulshof, K., Korhonen, H., Lagiou, P., ... Verhagen, H. (2008). Vitamin K2 added for nutritional purpose in foods for particular nutritional uses, food supplements and foods intended for the general population and vitamin K2 as a source of vitamin K added for nutritional purposes to foodstuffs, in the context of Regulation (EC) N° 258/97 – Scientific opinion of the panel on dietetic products, nutrition and allergies. *The EFSA Journal*, 822, 1–31.
- Carlone, G. M., & Anet, F. L. (1983). Detection of menaquinone-6 and a novel methyl-substituted menaquinone-6 in *Campylobacter jejuni* and *Campylobacter fetus* subsp. *Fetus*. *Journal of General Microbiology*, 129, 3385–3393.
- Cockayne, S., Adamson, J., Lanham-New, S., Shearer, M. J., Gilbody, S., & Torgerson, D. J. (2006). Vitamin K and the prevention of fractures: Systematic review and meta-analysis of randomized controlled trials. *Archives of Internal Medicine*, 166, 1256–1261.
- Daines, A. M., Payne, R. J., Humphries, M. E., & Abell, A. D. (2003). The synthesis of naturally occurring vitamin K and vitamin K analogues. *Current Organic Chemistry*, 7, 1–15.
- FAO. (2008). GRAS assessment – NattoPharma ASA, Menaquinone-7/MenaQ7. < <https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm264117.pdf> > .
- Fouquet, T., Humbel, S., & Charles, L. (2011). Tandem mass spectrometry of trimethylsilyl-terminated poly(dimethylsiloxane) ammonium adducts generated by electrospray ionization. *Journal of the American Society for Mass Spectrometry*, 22, 649–658.
- Gast, G. C., de Roos, N. M., Sluijs, I., Bots, M. L., Beulens, J. W., Geleijnse, J. M., ... van der Schouw, Y. T. (2009). A high menaquinone intake reduces the incidence of coronary heart disease. *Nutrition, Metabolism, and Cardiovascular Diseases: NMCD*, 19, 504–510.
- Geleijnse, J. M., Vermeer, C., Grobbee, D. E., Schurgers, L. J., Knapen, M. H., van der Meer, I. M., ... Witteman, J. C. (2004). Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam study. *The Journal of Nutrition*, 134, 3100–3105.
- Gundberg, C. M., Lian, J. B., & Booth, S. L. (2013). Vitamin K-dependent carboxylation of osteocalcin: Friend or foe? *Advances in Nutrition*, 3(2), 149–157.
- Hamidi, M. S., & Cheung, A. M. (2014). Vitamin K and musculoskeletal health in post-menopausal women. *Molecular Nutrition and Food Research*, 58(8), 1647–1657.
- Huang, B., Zheng, F., Fu, S., Yao, J., Tao, B., & Ren, Y. (2012). UPLC-ESI-MS/MS for determining *trans*- and *cis*-vitamin K1 in infant formulas: Method and applications. *European Food Research and Technology*, 235(5), 873–879.
- Huang, N., & Siegel, M. M. (1999). Automation of a fourier transform ion cyclotron resonance mass spectrometer for acquisition, analysis, and e-mailing of high-resolution exact-mass electrospray ionization mass spectral data. *Journal of the American Society for Mass Spectrometry*, 10, 1166–1173.
- Jinghe, X., Mizuta, T., & Ozaki, I. (2015). Vitamin K and hepatocellular carcinoma: The basic and clinic. *World Journal of Clinical Cases*, 3(9), 757–764.
- Kamao, M., Sahara, Y., Tsugawa, N., Uwano, M., Yamaguchi, N., Uenishi, K., ... Okano, T. (2007). Vitamin K content of foods and dietary vitamin K intake in Japanese young women. *Journal of nutritional science and vitaminology (Tokyo)*, 53(6), 464–470.
- Knauer, T. E., Siegfried, C., Willingham, A. K., & Matschiner, J. T. (1975). Metabolism and biological activity of *cis*- and *trans*-phyloquinone in the rat. *The Journal of Nutrition*, 105(12), 1519–1524.
- Lowenthal, J., & Rivera, G. M. V. (1979). Comparison of the activity of the *cis* and *trans* isomer of vitamin K1 in vitamin K – Deficient and coumarin anticoagulant p retreated rats. *The Journal of Pharmacology and Experimental Therapeutics*, 209(3), 330–333.
- Nannapaneni, N. K., Jalalpure, S. S., Muppavarapu, R., & Sirigiri, S. K. (2017). A sensitive and rapid UPLC-APCI-MS/MS bioanalytical method for quantification of endogenous and exogenous Vitamin K1 isomers in human plasma: Development, validation and first application to a pharmacokinetic study. *Talanta*, 164, 233–243.
- Nimptsch, K., Rohrmann, S., & Linseisen, J. (2008). Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European prospective investigation into cancer and nutrition (EPIC-Heidelberg). *The American Journal of Clinical Nutrition*, 87, 985–992.
- Plaza, S. M., & Lamson, D. W. (2005). Vitamin K2 in bone metabolism and osteoporosis. *Alternative Medicine Review*, 10(1), 24–35.
- Pucaj, K., Rasmussen, H., Möller, M., & Preston, T. (2011). Safety and toxicological evaluation of a synthetic vitamin K2, menaquinone-7. *Toxicology Mechanisms and Methods*, 21(7), 520–532.
- Sato, K., Inoue, S., & Saito, S. (1973). A new synthesis of vitamin K via  $\pi$ -allylnickel intermediates. *Journal of the Chemical Society, Perkin Transactions, 1*, 2289–2293.
- Sato, T., Yamada, Y., Ohtani, Y., Mitsui, N., Murasawa, H., & Araki, S. (2001). Production of menaquinone (Vitamin K2)-7 by *Bacillus subtilis*. *Journal of Bioscience and Bioengineering*, 91(1), 16–20.
- SCCS. (2010). Scientific Committee on consumer safety opinion on vitamin K1 (phytonadione). The SCCS adopted this opinion at 6th plenary meeting of 23 March 2010: < [https://ec.europa.eu/health/scientific\\_committees/consumer\\_safety/docs/sccs\\_o\\_014.pdf](https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_014.pdf) > .
- Scheiber, D., Veulemans, V., Horn, P., Chatrou, M. L., Potthoff, S. A., Kelm, M., ... Westenfeld, R. (2015). High-dose menaquinone-7 supplementation reduces cardiovascular calcification in a murine model of extrasosseous calcification. *Nutrients*, 7(8), 6991–7011.
- Schurgers, L. J., & Vermeer, C. (2000). Determination of phyloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. *Haemostasis*, 30, 298–307.
- Shea, M. K., & Booth, S. L. (2007). Role of vitamin K in the regulation of calcification. *International Congress Series*, 1297, 165–117.
- Shearer, M. J., & Newman, P. (2008). Metabolism and cell biology of vitamin K. *Thrombosis and Haemostasis*, 100, 530–547.
- Snyder, C. D., & Rapoport, H. (1974). Synthesis of menaquinones. *Journal of the American Chemical Society*, 96(26), 8046–8054.
- Spronk, H. M., Soute, B. A., Schurgers, L. J., Thijssen, H. H., De Mey, J. G., & Vermeer, C. (2003). Tissue specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. *Journal of Vascular Research*, 40, 531–537.
- Vermeer, C. (2012). Vitamin K: The effect on health beyond coagulation – An overview. *Food and Nutrition Research*, 56, 5329.
- Walther, B., Karl, J. P., Booth, S. L., & Boyaval, P. (2013). Menaquinones, bacteria, and the food supply: The relevance of dairy and fermented food products to vitamin K requirements. *Advances in Nutrition – American Society for Nutrition*, 4, 463–473.
- Weber, F., & Wiss, O. (1959). Die Reaktivierung der Bernsteinsäure-Cytochrom-c-Reduktase durch die Vitamine K1 und K2 und deren Isoprenologen. *Helvetica*, 42(1), 217–225.
- Weber, P. (2001). Vitamin K and bone health. *Nutrition*, 17(10), 880–887.
- Yamada, Y., Aoki, K., & Tahara, Y. (1982). The structure of the hexahydrogenated isoprenoid side-chain menaquinone with nine isoprene units isolated from *Actinomadura madurae*. *The Journal of General and Applied Microbiology*, 28, 321–329.
- Yamaguchi, M. (2014). Role of nutritional factor menaquinone-7 in bone homeostasis and osteoporosis prevention. *Integrative Molecular Medicine*, 1, 1–6.
- Yilmaz, B., Kadioglu, Y., Meral, K., & Onganer, Y. (2012). Determination of human growth hormone in pure and pharmaceutical dosage form by spectrofluorometry and high performance liquid chromatography. *Chemical Industry & Chemical Engineering Quarterly*, 18(3), 399–405.